Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
A Multicenter, Observational Prospective Study on Quality of Life (QOL) in Advanced Cancer Patients With Opioid-induced Constipation (OIC) Treated at Home With Naloxegol According to the Clinical Practice
Opioid-Induced Constipation (OIC) is often associated with a compromised quality of life of patients in palliative care (PC) setting. Among the Peripherally-Acting Mu-Opioid Receptor Antagonists, Naloxegol is the most effective to treat OIC and to improve OIC-related aspects of quality of life in patients with non-cancer pain.
This observational study aims to assess the impact of a 4-weeks Naloxegol therapy on the quality of life in advanced cancer patients with OIC assisted by a home PC program.
The study is enrolling cancer patients with OIC (defined according to Rome IV criteria) not relieved by first-line laxatives, starting the therapy with 25 mg/day of Naloxegol. The main parameters evaluated at the beginning of the therapy (T0) and after 28 days (T28) are: Patient Assessment of Constipation Quality-of-Life (PAC-QoL, 4 subscales: physical discomfort, psychosocial discomfort, worries and concerns, satisfaction), evaluation of objective (number of weekly evacuations) and subjective constipation (Bowel Function Index, BFI, normal score<30), pain assessment by NRS.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
BO
-
Bologna, BO, Italien, 40128
- Fondazione ANT Italia ONLUS
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- cancer patients with advanced disease;
- age higher than 18 years;
- mentally competent;
- naloxegol therapy for no more than 1 week according to clinical practice;
- sign of a written informed consent.
Exclusion Criteria:
- patient with pain not controlled by opioids;
- therapy with other PAMORAs;
- intestinal obstruction;
- risk of intestinal perforation.
- severe renal failure.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Patient Assessment of Constipation Quality-of-Life (PAC-QoL) score
Tidsram: 4 weeks
|
Change of quality of life evaluated by Patient Assessment of Constipation Quality-of-Life (PAC-QoL) at T0 and T28.
Each item of the 28-item questionnaire was scored on a 5-point Likert-type scale from 0 to 4, with (0 = none/not at all, 1 = a little bit/a little bit of the time, 2 = moderately/some of the time, 3 = quite a bit/most of the time, 4 = extremely/all the time).
Scores were reported overall and for each of the four subscales (physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction).
An improvement (reduction) of ≥1 point in PAC-QOL score was considered clinically significant based on previous validation studies.
|
4 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective constipation
Tidsram: 4 weeks
|
Change of objective constipation evaluated by number of weekly evacuations.
|
4 weeks
|
|
Subjective constipation
Tidsram: 4 weeks
|
Change of subjective constipation evaluated by Bowel Function Index (BFI).
The BFI is a physician-administered, patient-assessment scale made up of three items: (1) ease of defecation, (2) feeling of incomplete bowel evacuation, and (3) personal judgement of constipation during the last 7 days.
The physician asks the patient to rate his or her impression of each of the three items during the previous week on a scale from 0 to 100, with 0 signifying 'not at all' and 100 signifying 'very strong'.
The score is then calculated as the average of the three components of the scale with each component being weighted equally.
The BFI total score remains on a scale of 0 to 100 with higher scores indicating greater constipation.
|
4 weeks
|
|
Pain (Numeric Rating Scale)
Tidsram: 4 weeks
|
Change of pain assessed by Numeric Rating Scale (NRS).
The NRS is a 11-points numeric scale through participants were asked to rate their average pain intensity by selecting a single number from 0 to 10. Higher scores indicate a more severe pain.
|
4 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Enrico Ruggeri, MD, Fondazione ANT Italia ONLUS
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Kemiskt inducerade störningar
- Substansrelaterade störningar
- Tecken och symtom, matsmältningssystemet
- Narkotikarelaterade störningar
- Förstoppning
- Opioid-inducerad förstoppning
- Läkemedels fysiologiska effekter
- Agenter från det perifera nervsystemet
- Sensoriska systemagenter
- Narkotiska antagonister
- Naloxegol
Andra studie-ID-nummer
- 293/2018/OSS/AUSLBO
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .